Janssen-Cilag B.V.: Clinical Trials

12 completed, 1 unknown. 2 Phase 4, 1 Not applicable, 1 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 4	2	Completed 2
Not applicable	1	Completed 1
Phase 2	1	Completed 1
Phase 3	1	Completed 1

Follow Janssen-Cilag B.V.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Respiratory Syncytial Virus (RSV) Burden in Older Adults in Primary Care in The Netherlands RSV Infection		Unknown	UMC Utrecht	100	2022-11-01	2024-03-19
A nUtrition and Lifestyle Intervention in Patients With Pulmonary Arterial HypertensIon E-learning, Diet - Pulmonary Arterial Hypertension	Not applicable	Completed	Amsterdam UMC, location VUmc	40	2019-10-20	2022-04-08
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms Chronic Hepatitis C		Completed	Foundation for Liver Research	20	2012-05-01	2015-03-11
A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa Ustekinumab - Hidradenitis Suppurativa	Phase 2	Completed	University Medical Center Groningen	20	2012-05-01	2024-04-18
INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia Paliperidone ER - Schizophrenia		Completed	Janssen-Cilag B.V.	27	2008-03-01	2014-04-28
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Bortezomib - Multiple Myeloma, Hematological Neoplasms		Completed	Janssen-Cilag B.V.	11	2006-09-01	2015-04-16
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2) Epoetin alfa - Anemia, Neoplasms		Completed	Janssen-Cilag B.V.	1927	2005-10-01	2012-11-06
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia Darbepoetin alfa, Epoetin alfa - Anemia, Neoplasms		Completed	Janssen-Cilag B.V.	492	2005-06-01	2014-05-07
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands bortezomib - Multiple Myeloma, Hematological Neoplasms		Completed	Janssen-Cilag B.V.	331	2004-11-01	2014-01-14
An Observational Study of Blood Management Techniques in Oncology Surgical Treatment Oncological surgery - Anemia, Blood Loss, Surgical		Completed	Janssen-Cilag B.V.	488	2004-07-01	2014-04-28
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy epoetin alfa - Anemia, Neoplasms	Phase 4	Completed	Janssen-Cilag B.V.	110	2003-08-01	2011-05-19
The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease Epoetin Alfa - Anemia	Phase 3	Completed	Janssen-Cilag B.V.	176	1999-11-01	2011-02-01
A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy Epoetin alfa - Anemia, Neoplasm	Phase 4	Completed	Janssen-Cilag B.V.	316	1999-11-01	2011-01-14

Conditions studied

Anemia (6)  ·  Neoplasms (5)  ·  Hematologic Neoplasms (2)  ·  Multiple Myeloma (2)  ·  Blood Loss, Surgical (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Hemorrhage (1)  ·  Hepatitis C (1)  ·  Hepatitis C, Chronic (1)  ·  Hidradenitis Suppurativa (1)  ·  Pulmonary Arterial Hypertension (1)  ·  RNA Virus Infections (1)  ·  Renal Insufficiency (1)  ·  Respiratory Syncytial Virus Infections (1)  ·  Schizophrenia (1)

Interventions

Epoetin Alfa (5)  ·  Bortezomib (2)  ·  Darbepoetin alfa (1)  ·  Diet (1)  ·  Paliperidone Palmitate (1)  ·  Ustekinumab (1)

Countries

Netherlands (9)

Top investigators

A. Boonstra, PhD (1)  ·  Anton Vonk Noordegraaf, prof. dr. (1)  ·  Louis Bont, MD, PhD (1)

Results publications

PMID 15953714, PMID 18343652